Evidence map›Paper›PMID 39558361›Full record

ArticleJournal of nanobiotechnology2024

Physical, biochemical, and biological characterization of olive-derived lipid nanovesicles for drug delivery applications.

Zhu Zhao, Jerome Lacombe, Laurianne Simon, Noelia M Sanchez-Ballester, Ashkan Khanishayan, Naina Shaik, Kallie Case, Pierre-Yves Dugas, Mathieu Repellin, Giovanna Lollo and 5 more

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Green nanomedicine for cancer therapy.Chinese medical journal · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhu Zhao *Center for Applied NanoBioscience and Medicine, College of Medicine Phoenix, University of Arizona, Phoenix, AZ, 85004, USA.
Jerome Lacombe *Center for Applied NanoBioscience and Medicine, College of Medicine Phoenix, University of Arizona, Phoenix, AZ, 85004, USA. jlacombe@arizona.edu.
Laurianne Simon *ICGM, CNRS, ENSCM, University of Montpellier, Montpellier, 34000, France.
Noelia M Sanchez-BallesterICGM, CNRS, ENSCM, University of Montpellier, Montpellier, 34000, France.
Ashkan KhanishayanCenter for Applied NanoBioscience and Medicine, College of Medicine Phoenix, University of Arizona, Phoenix, AZ, 85004, USA.
Naina ShaikCenter for Applied NanoBioscience and Medicine, College of Medicine Phoenix, University of Arizona, Phoenix, AZ, 85004, USA.
Kallie CaseCenter for Applied NanoBioscience and Medicine, College of Medicine Phoenix, University of Arizona, Phoenix, AZ, 85004, USA.
Pierre-Yves DugasUniversity of Lyon, Université Claude Bernard Lyon 1, CNRS, CP2M UMR 5128, Villeurbanne, France.
Mathieu RepellinUniversity of Lyon, Université Claude Bernard Lyon 1, CNRS, LAGEPP UMR 5007, 43 bd 11 Novembre 1918, Villeurbanne, 69622, France.
Giovanna LolloUniversity of Lyon, Université Claude Bernard Lyon 1, CNRS, LAGEPP UMR 5007, 43 bd 11 Novembre 1918, Villeurbanne, 69622, France.
Ian SoulairolICGM, CNRS, ENSCM, University of Montpellier, Montpellier, 34000, France.
Ashlee F HarrisCenter for Applied NanoBioscience and Medicine, College of Medicine Phoenix, University of Arizona, Phoenix, AZ, 85004, USA.
Michael GordonHonorHealth Research Institute, Scottsdale, AZ, 85258, USA.
Sylvie Begu *ICGM, CNRS, ENSCM, University of Montpellier, Montpellier, 34000, France.
Frederic Zenhausern *Center for Applied NanoBioscience and Medicine, College of Medicine Phoenix, University of Arizona, Phoenix, AZ, 85004, USA. fzenhaus@arizona.edu.

Funding

Sample Engineering CoreU19AI067773 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FORNACE, ALBERT J · 2005 to 2024
$105.4M
National Institute of Allergy and Infectious Diseases 5U19AI067773NIAID NIH HHS U19 AI067773
6 · The paper itself

Abstract

Extracellular vesicles (EVs) have shown great promise as drug delivery system (DDS). However, their complex and costly production limit their development for clinical use. Interestingly, the plant kingdom can also produce EV-like nanovesicles that can easily be isolated and purified from a large quantity of raw material at a high yield. In this study, olive-derived nanovesicles (ODNVs) were isolated from raw fruits using serial centrifugations and their physical and biological features characterized to demonstrate their promising potential to be used as a DDS. Nanotracking particle analysis indicated an average size of 109.5 ± 3.0 nm and yield of 10

Indexed as

DoxorubicinDrug Delivery SystemsExtracellular VesiclesNanoparticlesOleaCell Line, TumorCell SurvivalDrug CarriersFruitHumansLipid BilayersLipidsParticle SizeDoxorubicinDrug CarriersLipid BilayersLipids

Identifiers

PMID39558361
PMCPMC11575425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.